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Background: Angiotensin I-converting enzyme (ACE) inhibitors have been reported to reduce mortality in patients
with hypertension. Compared to chemosynthetic drugs, ACE inhibitors derived from natural sources such as food
proteins are believed to be safer for consumption and to have fewer adverse effects. Some edible mushrooms have
been reported to significantly reduce blood pressure after oral administration. In addition, mushrooms are known
to be rich in protein content. This makes them a potential source of ACE inhibitory peptides. Hence, the objective
of the current study was to isolate and characterise ACE inhibitory peptides from an edible mushroom, Pleurotus
cystidiosus.
Methods: ACE inhibitory proteins were isolated from P. cystidiosus based on the bioassay guided purification steps,
i.e. ammonium sulphate precipitation, reverse phase high performance liquid chromatography and size exclusion
chromatography. Active fraction was then analysed by LC-MS/MS and potential ACE inhibitory peptides identified
were chemically synthesized. Effect of in vitro gastrointestinal digestions on the ACE inhibitory activity of the
peptides and their inhibition patterns were evaluated.
Results: Two potential ACE inhibitory peptides, AHEPVK and GPSMR were identified from P. cystidiosus with
molecular masses of 679.53 and 546.36 Da, respectively. Both peptides exhibited potentially high ACE inhibitory
activity with IC50 values of 62.8 and 277.5 μM, respectively. SEC chromatograms and BIOPEP analysis of these
peptides revealed that the peptide sequence of the hexapeptide, AHEPVK, was stable throughout gastrointestinal
digestion. The pentapeptide, GPSMR, was hydrolysed after digestion and it was predicted to release a dipeptide
ACE inhibitor, GP, from its precursor. The Lineweaver-Burk plot of AHEPVK showed that this potent and stable
ACE inhibitor has a competitive inhibitory effect against ACE.
Conclusion: The present study indicated that the peptides from P. cystidiosus could be potential ACE inhibitors.
Although these peptides had lower ACE inhibitory activity compared to commercial antihypertensive drugs, they
are derived from mushroom which could be easily obtained and should have no side effects. Further in vivo
studies can be carried out to reveal the clear mechanism of ACE inhibition by these peptides.
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Angiotensin I-converting enzyme (ACE) inhibitors have
been reported to reduce mortality in patients with
hypertension [1]. These drugs act as vasodilators by
reducing the levels of angiotensin II in the renin-
angiotensin system or by inhibiting the degradation of
bradykinin in the kallikrein-kinin system [2]. They have
been prescribed as first-line treatment for hypertension
in patients with type 1 diabetes, proteinuria or left
ventricular systolic dysfunction (LVSD) [3]. Captopril
was the first orally active ACE inhibitor to be synthesised
[4]. Compared to chemosynthetic drugs, ACE inhibitory
peptides derived from natural sources such as food
proteins are believed to be safer for consumption and
to have fewer adverse effects. Many ACE inhibitory
peptides have been isolated from food proteins such as
salmon, tuna, rice, buckwheat, soybean and whey [5-10].
Some of these ACE inhibitory peptides have exhibited
stability against gastrointestinal digestion and produce a
blood pressure-lowering effect when tested in vivo [6,8].
Mushrooms have received increasing attention in recent
years because of their health-stimulating properties and
medicinal effects. Some edible mushrooms have been
reported to significantly reduce blood pressure after oral
administration. Examples are Pleurotus cornucopiae,
Lyophyllum decastes, P. nebrodensis, Grifola frondosa,
P. sajor-caju and Lentinula edodes [11-16]. The protein
content in mushrooms is ranked below most animal
meats but above most other foods, such as milk, vege-
tables and fruits [17]. Thus, this makes them a good
starting material for the identification of peptides with
biological activities including ACE inhibition activity. ACE
inhibitory peptides have been successfully purified from
edible mushrooms, such as G. frondosa, P. cornucopiae,
Pholiota adiposa and Tricholoma giganteum [18-21].
Among the most common edible mushrooms available
in Malaysia, P. cystidiosus has exhibited the most
potent ACE inhibitory activity. Proteomic analysis of
P. cystidiosus has shown that it contains potential ACE
inhibitory peptides [22]. Therefore, the objective of
the current study was to isolate and characterise ACE
inhibitory peptides from P. cystidiosus.
Methods
Materials
Sporocarps (or fruiting bodies) of P. cystidiosus were
obtained from Gano Farm Sdn. Bhd. and authenticated
by morphology and molecular methods by experts in
the Mushroom Research Centre, University of Malaya,
Malaysia. Herbarium voucher specimen (KLU-M 1234)
was deposited in the Kuala Lumpur Herbarium, University
of Malaya. Culture for this species was deposited at
Mushroom Research Centre culture collection, University
of Malaya and was assigned a culture code (KUM 61204).All solvents and chemicals used in this study were of
analytical and HPLC grade. Acetonitrile and trifluoroa-
cetic acid (TFA) were obtained from Merck (Darmstadt,
Germany). ACE from rabbit lung, hippuryl-L-histidyl-
L-leucine (HHL) and gastrointestinal proteases (pepsin,
trypsin and α-chymotrypsin) were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Purification of potential ACE inhibitory peptides by size
exclusion chromatography (SEC)
Protein extraction from P. cystidiosus was done based on
a previous study [22]. Briefly, 1000 g of fresh fruiting
bodies of P. cystidiosus were cleaned, sliced and blended
with distilled water at a ratio of 1:2 (w/v). The mixture
was filtered and centrifuged to remove unwanted debris.
Proteins were precipitated out from the water extract
using ammonium sulphate at 10-100% salt saturation.
Precipitated proteins showing the highest ACE inhibitory
activity were then fractionated by reverse phase high
performance liquid chromatography (RPHPLC). Based
on the results reported by Lau et al., [22], the active
RPHPLC fraction was E5PcF3. Thus, it was further
purified in the current study by SEC using a Biosep
SEC-S2000 column (300 × 7.8 mm, Phenomenex, Torrance,
CA, USA). Analysis was performed by injecting 20 μl
of E5PcF3 on an HPLC system equipped with an SCL-
10AVP system controller, LC-10ATVP solvent delivery
unit, SPD-M10AVP UV–vis diode array detector and
DGU-12A degasser (Shimadzu, Kyoto, Japan). The mobile
phase consisted of 45% acetonitrile containing 0.1% TFA.
The flow rate was 1.0 ml/min and the effluent was moni-
tored at 214 nm. E5PcF3 was fractionated according to the
peaks obtained. After repeated injections, the fractions
collected were freeze-dried and the ACE inhibitory activity
of the SEC fractions was determined at a concentration of
1 μg/ml protein. The SEC fraction with the highest ACE
inhibitory activity was analysed by liquid chromatography
mass spectrometry for sequence identification.
Estimation of the protein content in the SEC
protein fraction
The protein content of the SEC fractions was estimated
using the Pierce® Bicinchoninic Acid (BCA) Protein Assay
Kit (Thermo Scientific, Rockford, IL, USA) according
to the protocol provided by the manufacturer. The ab-
sorbance values were measured using a Sunrise™ ELISA
microplate reader (Tecan, Grödig, Austria) at 562 nm.
The protein content was determined by comparing the
absorbance value of the samples with a standard curve
of bovine serum albumin.
Assay of ACE inhibitory activity
In the current study, ACE inhibitory activity was deter-









Figure 1 SEC chromatogram of E5PcF3. Following RPHPLC, active protein E5PcF3 was further separated using a Biosep SEC-S2000 column
(300 × 7.8 mm). The mobile phase consisted of 45% acetonitrile containing 0.1% TFA eluted at a flow rate of 1.0 ml/min. Seven peaks eluted from
SEC column labelled C1 to C7 were collected and re-evaluated for ACE inhibitory activity.
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carried out according to the protocol provided by the
manufacturer. Absorbances of the reactions were mea-
sured using a Sunrise® ELISA microplate reader (Tecan,
Grödig, Austria) at 450 nm. The ACE inhibitory activity
of the samples was calculated using the formula given in
the protocol. The concentration of the ACE inhibitor
required to inhibit 50% of ACE activity under the above
assay conditions was defined as the IC50.Table 1 Percentages of protein recovery yield and
percentages of ACE inhibitory activity of the SEC fractions
SEC fraction % Recovery % ACE inhibitory activity*
C1 3.6 27.44 ± 2.66 c
C2 3.9 5.56 ± 2.18 a
C3 24.6 7.47 ± 0.82 a
C4 12.8 7.98 ± 4.72 aLiquid chromatography-mass spectrometry (LC-MS/MS)
Identification of the peptide sequences present in SEC
fraction 1 was carried out by LC-MS/MS at Proteomics
International Pty Ltd, WA, Australia. Briefly, the SEC
fraction was digested with trypsin and the peptides
extracted were analysed by electrospray ionisation mass
spectrometry using an Ultimate 3000 nano HPLC system
(Dionex, Sunnyvale, CA, USA) coupled to a 4000 QTRAP
mass spectrometer (Applied Biosystems, Foster City,
CA, USA). Peptides were loaded onto a C18 PepMap100,
3 μm (LC Packings) column and separated with a linear
gradient of water/acetonitrile/0.1% formic acid (v/v).
Protein identification was carried out using Mascot
sequence matching software (Matrix Science) with the
Ludwig NR database.C5 9.6 5.93 ± 2.24 a
C6 12.3 8.70 ± 2.54 ab
C7 16.6 13.60 ± 3.99 b
Total 83.4 -
*ACE inhibitory activity of SEC fractions was tested at 1 μg/ml protein and
expressed as mean ± standard deviation (n = 3). Different letters within a
column indicate significant differences (p < 0.05) in the percentage of ACE
inhibitory activity analysed by one-way ANOVA. SEC fraction highlighted in
bold was selected for further analysis.Peptide synthesis
The two identified potential ACE inhibitory peptides,
AHEPVK and GPSMR were chemically synthesised by
Peptron, Inc., Republic of Korea. The purity of the
synthesised peptides was >98% measured by RPHPLC
and MS analysis.Effect of simulated gastrointestinal digestion on the
selected peptides
The stability of the synthesised peptides against gastro-
intestinal proteases was assessed in vitro by the method
of Wu and Ding [23]. The peptide solution (0.1 mg/ml,
0.5 ml) was incubated with 0.5 ml of a 0.05% pepsin
solution (0.1 M HCl at pH 2.0) for 2.5 hrs at 37°C. In
the successive pepsin-pancreatin digestion test, the
peptide solution was adjusted to pH 8.0 after pepsin
digestion. Then, 0.5 ml of pancreatin solution [potassium
phosphate buffer (0.1 M, pH 8.0) containing 0.025% (w/v)
chymotrypsin and 0.025% (w/v) trypsin] was added to
the solution. The mixture was incubated for another
2.5 hrs at 37°C. The control (without digestion) consisted
of peptide solution incubated in buffer solutions (HCl
and potassium phosphate buffer) and was carried out
alongside the experiment. After enzymatic treatment,
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were boiled for 10 min to stop the digestion and then
centrifuged at 10,000 rpm for 10 min. The supernatants
were freeze-dried and used for the measurement of ACE
inhibitory activity. The stability of the purified peptides
against gastrointestinal enzymes was analysed by SEC.
Determination of the inhibition pattern on ACE activity
The inhibition pattern of peptide AHEPVK on ACE
activity was determined spectrophotometrically usingI Molecular mass (Da)
679.53


































Figure 2 LC-MS/MS spectra of peptides (I) AHEPVK and (II) GPSMR wi
inhibitory activity.HHL as substrate. Basically, 20 μl of the ACE solution
(0.1 UN/ml) and 50 μl of peptide were incubated with
200 μl of various HHL concentrations (0.63, 1.25, 2.50
and 5.00 mM). The enzymatic reaction was terminated
by the addition of 250 μl of 1.0 M HCl. The liberated
hippuric acid was extracted with ethyl acetate and
evaporated under vacuum condition. The hippuric acid
residue was re-dissolved in 1.0 ml of distilled water and
the absorbance was determined at 228 nm using a





















th the estimated molecular mass and IC50 value of ACE
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ities were measured in the presence (0.05 and 0.50 mg/ml)
and absence (control) of peptide. The kinetic of ACE
inhibition was determined by Lineweaver-Burk plots.
Statistical analysis
The analysis of ACE inhibitory activity was carried out
in triplicate and result was reported as mean ± standard
deviation. Mean differences of ACE inhibitory activity
in SEC fractions was analyzed using one-way ANOVA
in Statgraphics Plus 3.0 at p < 0.05.Results and discussion
Purification of potential ACE inhibitory peptides by SEC
The RPHPLC fraction of E5PcF3 was further fraction-
ated by SEC into seven fractions (C1 to C7), as shown
in Figure 1. Referring to Table 1, a total of 83.4% of the
proteins were recovered by SEC. The percentages of
protein collected from fractions C1 to C7 were in the
range of 3.6 to 24.6%. Each SEC fraction was tested for
ACE inhibitory activity at a concentration of 1 μg/ml.
Among the seven SEC fractions, C1 exhibited significantly
higher ACE inhibitory activity, where 27.44% of ACE
enzyme activity was blocked. Therefore, C1 was selected
for further analysis by LC-MS/MS.
Identification of ACE inhibitory peptide by LC-MS/MS
The amino acid sequences of the peptides in C1 were
determined by LC-MS/MS. Two potential ACE inhibi-
tory peptides were identified. The LC-MS/MS spectra
of these peptides are shown in Figure 2. Peptides
AHEPVK and GPSMR had molecular masses of 679.53
and 546.36 Da, respectively. A low molecular weight isFigure 3 Effect of simulated gastrointestinal digestion on the ACE inh
peptide solutions (0.1 mg/ml) were incubated in buffer solutions (HCl and
with 0.05% pepsin solution for 2.5 hrs at 37°C. P + T + C: The peptide soluti
further incubated in pancreatin solution for another 2.5 hrs at 37°C. The ACan added advantage for a potent ACE inhibitor because
large peptide molecules are restricted from fitting into
the active site of ACE [24]. Interestingly, the two peptides
in the current study were found to have similar sequence
compared to ACE inhibitory peptides from other food
sources. For instance, similar to AHEPVK, potential ACE
inhibitor from sea squirt (AHIII) has alanine and histidine
at the N-terminal [25]. GPSMR has similar peptide se-
quence with peptide from sweet potato (GPCSR) [26].
In the current study, peptide AHEPVK exhibited po-
tentially high ACE inhibitory activity with an IC50 value
of 62.8 μM. This is lower than the IC50 value of ACE
inhibitory peptides isolated from other edible mushrooms,
i.e. G. frondosa (129.7 μM), P. adiposa (254 μM) and
P. cornucopiae (277.3 μM) [18,20,21]. On the other
hand, peptide GPSMR inhibited 50% of ACE activity
at a concentration of 277.5 μM, which is similar to the
IC50 values of P. adiposa and P. cornucopiae [18,20].
The peptides in the current study have lower ACE
inhibitory activity than proteins from other food sources.
Hexapeptide from milk (PYVRYL) and pentapeptide
from bonita fish (LKPNM) have exhibited IC50 value
of 2.4 μM [27,28]. Peptide LRIPVA from spinach
inhibited 50% of the ACE at a concentration as low as
0.38 μM [29]. However, there were also studies reported
on similar IC50 value with the current study. Peptides
GTEKC and GPCSR from sweet potato exhibited IC50
values of 61.67 and 275.8 μM, respectively [26,30].
There are several ACE inhibitory peptides from food
sources that have been sold in Japan and Canada.
Examples are Vasotensin®, PeptACE™ and Valtyron® [31].
These products were claimed to be suitable for treating
mild hypertension and free of side effects [32,33]. This
may suggest that ACE inhibitors from natural sources canibitory activity of peptides AHEPVK and GPSMR. Control: The
potassium phosphate buffer). P: The peptide solutions were incubated
ons were successively digested with pepsin for 2.5 hrs. They were
E inhibitory activity are expressed as mean ± standard deviation (n = 3).
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to cause side effects such as cough, skin rashes, taste dis-
turbance and angioedema [34]. Even though peptides
from edible mushrooms have lower ACE inhibitory
activity compared to peptides from other food sources,
in vivo studies of peptides from mushrooms, P. adiposa
and P. cornucopiae have shown similar antihypertensiveFigure 4 Stability of peptide AHEPVK against gastrointestinal enzyme
Biosep SEC-S2000 column (300 × 7.8 mm). Mobile phase consisted of 45%
Peptide was eluted as peak at retention time illustrated in the box. A: Pure
solutions (control); C: The peptide solution was incubated with 0.05% peps
digested with pepsin for 2.5 hrs. They were further incubated in pancreatineffect with the commercial drug, captopril [18,20].
Additionally, mushrooms have an added advantage of
low probability to cause food allergy. Therefore, the
peptides tested in the current study, particularly
AHEPVK could be applied as ingredient in functional
foods, dietary supplements or pharmaceuticals as an
antihypertensive agent.s observed by SEC chromatograms. Separation was performed on a
acetonitrile containing 0.1% TFA eluted at a flow rate of 1.0 ml/min.
peptide; B: The peptide solution (0.1 mg/ml) was incubated in buffer
in solution for 2.5 hrs at 37°C; D: The peptide solution was successively
solution for another 2.5 hrs at 37°C.
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selected peptides
Proteins or peptides delivered by the oral route have to
be able to maintain their biological activity throughout
the digestion process in the gastrointestinal tract before
they reach their target site inside the body. The most
important sites for the digestion of proteins and
peptides are the stomach and small intestine. TheyFigure 5 Stability of peptide GPSMR against gastrointestinal enzymes
Biosep SEC-S2000 column (300 × 7.8 mm). Mobile phase consisted of 45%
was eluted as peak at retention time illustrated in the box. A: Pure peptide
(control); C: The peptide solution was incubated with 0.05% pepsin solutio
with pepsin for 2.5 hrs. They were further incubated in pancreatin solutioncontain gastrointestinal enzymes such as pepsin (stomach),
trypsin and chymotrypsin (small intestine) [35]. Prelimin-
ary experiments using gastrointestinal enzyme incubation
in vitro provided an easy method to evaluate the fate of
these peptides after oral administration.
Referring to Figure 3, both peptides had exhibited high
ACE inhibitory activity after gastrointestinal digestion.
Without gastrointestinal digestion, AHEPVK inhibitedobserved by SEC chromatograms. Separation was performed on a
acetonitrile containing 0.1% TFA at a flow rate of 1.0 ml/min. Peptide
; B: The peptide solution (0.1 mg/ml) was incubated in buffer solutions
n for 2.5 hrs at 37°C; D: The peptide solution was successively digested
for another 2.5 hrs at 37°C.
Lau et al. BMC Complementary and Alternative Medicine 2013, 13:313 Page 8 of 10
http://www.biomedcentral.com/1472-6882/13/31380.27% of ACE activity. Its activity was enhanced to
95.38% after digestion by pepsin and maintained at
95.94% after pepsin-pancreatin digestion. Compared to
AHEPVK, GPSMR exhibited greater enhancement after
digestion. The ACE inhibitory activity increased from
67.08% to 92.22% after digestion by pepsin. Pepsin-
pancreatin digestion further enhanced the ACE inhibitory
activity to 96.05%. Previous studies have reported on
peptides which were resistant to further gastrointestinal
digestion and maintain their biological activity after
digestion [36]. However, some peptides could undergo
further hydrolysis by gastrointestinal enzymes to release
true inhibitors [37].
In order to verify the stability of these peptides, the
changes without and following gastrointestinal digestion
were analysed by SEC. The chromatograms are illus-
trated in Figures 4 and 5. Peaks for buffer (HCl and
potassium phosphate buffer) were eluted at approxi-
mately 9 and 11 min. This may explained the detection
of two extra peaks in the chromatograms. The BIOPEP
database (http://www.uwm.edu.pl/biochemia/index.php/
en/biopep) is an online program that can serve as a tool
to predict possible proteolysis products by gastrointestinal
enzymes and define the possible biological activity of the
proteolysis fragments [38]. Therefore, the predicted prote-
olysis activity analysed by the BIOPEP database was com-
pared with the SEC chromatograms of AHEPVK and
GPSMR in the current study.
According to BIOPEP, AHEPVK was not hydrolysed
by the three proteolytic enzymes. It was predicted to
remain stable throughout the digestion process. Referring
to Figure 4, the peptide AHEPVK, which was eluted
at 7.80 min, showed high intensity in the SEC chro-
matograms of the control and after digestion. This con-
firmed the stability of AHEPVK against digestive
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Figure 6 Kinetics of the synthetic peptide AHEPVK. ACE inhibitory activ
concentrations of the peptides (0.00, 0.05 and 0.50 mg/ml). Lineweaver-Bur
expressed as mean ± standard deviation (n = 3).that the preferential parameters for hexapeptides with
potent ACE inhibitory activity are stereo and hydrophobic
properties. Jimsheena and Gouda had shown the im-
portant role of stereo-specificity of amino acid residue
in ACE inhibitory activity. Based on their study, tripep-
tide IKP that contained L-lysine exhibited potent ACE
inhibitory activity. However, replacement of the L-
lysine with D-lysine caused the peptide to lose its ACE
inhibitory property [40]. Hydrophobicity of amino acids
has been indicated to have the greatest influence on
ACE inhibitory activity. According to Pripp and co
workers, hydrophobicity of C-terminal enhanced the
ACE inhibitory activity of potential peptides up to six
amino acids in length [41]. In the current study, the
stereoisomer effect of AHEPVK on ACE inhibition was
not definitive due to the unknown stereo structure of
the synthesized peptide. However, based on the peptide
sequence, hydrophobicity may have contributions in the
high ACE inhibitory activity of AHEPVK both before
and after digestion.
Referring to Figure 5, the peptide peak of GPSMR at a
retention time of 8.23 min was shifted and became
broader after gastrointestinal digestion. Theoretically,
smaller peptides would be eluted from the SEC column
at a later time [42]. This may suggest that the peptide
GPSMR had been hydrolysed into smaller fragments that
were eluted together with gastrointestinal enzymes,
resulting in a broad peak at 8.36 min. This is in line with
the results obtained by BIOPEP analysis. According to
the database, GPSMR was predicted to release fragments
of GP, SM and R from its precursor after gastrointestinal
digestion. Interestingly, dipeptide GP has been previously
reported to exhibit ACE inhibitory activity with an
IC50 value of 252.63 μM [43]. Therefore, the enhanced
ACE inhibitory activity of GPSMR after gastrointestinal
digestion was most probably due to the release of GP.1 1.5
/M)
g/ml 0.50 mg/ml
ity was determined in the absence and presence of different
k plot was constructed using values of 1/v against 1/ [S]. Values are
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Peptide AHEPVK exhibited the most potent ACE inhibi-
tory activity (IC50 62.8 μM) and it shows stability against
gastrointestinal digestion. Therefore, it was selected to de-
termine its inhibition pattern against the ACE enzyme.
According to the Lineweaver-Burk plot in Figure 6, pep-
tide AHEPVK showed a competitive inhibition pattern
against the ACE. This suggests that the peptide might
bind to the active site of ACE to block it from binding to
the substrate. Moreover, ACE has been reported to show
preference for competitive inhibitors that contain a hy-
drophobic amino acid at the third position from the
C-terminal [44,45]. This is in accordance with the amino
acid sequence of AHEPVK which might explain the
competitive inhibition pattern exhibited by this peptide.
The competitive inhibition pattern exhibited by AHEPVK
is similar to ACE inhibitory peptides purified from the
edible mushrooms G. frondosa, P. cornucopiae, P. adiposa
and T. giganteum [18-21]. In addition, a commercial ACE
inhibitor and antihypertensive drug, captopril, also inhibits
ACE in a competitive manner [4].
Conclusion
In the current study, peptides isolated from P. cystidiosus
were shown to be potential ACE inhibitors. Peptide
AHEPVK exhibited a high IC50 value (62.8 μM) and its
peptide sequence remained stable following gastrointestinal
digestion. It exhibited a competitive inhibition pattern
against ACE. Peptide GPSMR was predicted to release
a dipeptide ACE inhibitor, GP, from its precursor after
gastrointestinal digestion. Although these peptides had
lower ACE inhibitory activity compared to commercial
antihypertensive drugs, they are derived from food
sources and should have no side effects.
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